隐形素对骨健康的影响
Jakob Starup-Linde1, Katrine Hygum, Bente Langdahl
1Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus N, Denmark.
Current opinion in endocrinology, diabetes, and obesity
|June 19, 2023
概括
像GLP-1和GIP这样的胰岛素激素可以通过减少再吸收来有益于骨健康. 然而,GLP-1治疗的减肥可能会抵消这些骨效应,需要进一步研究.
科学领域:
- 内分泌学 在内分泌学.
- 骨生物学 骨生物学 骨生物学
- 代谢疾病 代谢疾病
背景情况:
- 胰岛素激素,葡萄糖类-1 (GLP-1) 和胃抑制 (GIP),影响葡萄糖代谢.
- 新出现的证据表明,这些激素也会影响骨健康,影响骨的再吸收和形成.
研究的目的:
- 审查最近关于隐形素对骨健康影响的研究.
- 收集关于GLP-1和GIP对骨代谢和骨折风险的影响的证据.
主要方法:
- 在过去一年内发表的临床前和临床研究的文献综述.
- 对有关因克雷受体类 analog 和骨折风险的流行病学数据的分析.
主要成果:
- 临床前研究表明GLP-1和GIP对骨有直接有益的影响.
- 流行病学数据显示,GLP-1类似物没有降低骨折风险,可能是由于混减肥效应.
- GIP显示骨吸收减少和骨形成增加;注意到GLP-2的潜在添加效应.
结论:
- 基于因克雷的疗法可能会给骨带来好处,但减肥效应需要考虑.
- 对GIP或联合GIP/GLP-2的长期数据是必要的,以充分了解它们对骨的影响和安全性.
相关概念视频
Glucagon-like Receptor Agonists
369
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
369
Dipeptidyl Peptidase 4 Inhibitors
216
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
216
Oral Hypoglycemic Agents: Glinides
190
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
190
Hormones and Bone Tissue
2.8K
The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
2.8K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
218
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
218
Oral Hypoglycemic Agents: Biguanides and Glitazones
240
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
240


